EMBRACE CHANGE ACQUISITION C (EMCG) Fundamental Analysis & Valuation

NASDAQ:EMCG • KYG3034H1092

Current stock price

11 USD
-1.2 (-9.84%)
Last:

This EMCG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EMCG Profitability Analysis

1.1 Basic Checks

  • EMCG had positive earnings in the past year.
  • EMCG had a negative operating cash flow in the past year.
  • In multiple years EMCG reported negative net income over the last 5 years.
  • EMCG had a negative operating cash flow in each of the past 5 years.
EMCG Yearly Net Income VS EBIT VS OCF VS FCFEMCG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 1M -1M 2M

1.2 Ratios

Industry RankSector Rank
ROA 3.96%
ROE 5.18%
ROIC N/A
ROA(3y)3.45%
ROA(5y)N/A
ROE(3y)4.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EMCG Yearly ROA, ROE, ROICEMCG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 2 4 6

1.3 Margins

  • EMCG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EMCG Yearly Profit, Operating, Gross MarginsEMCG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. EMCG Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, EMCG has less shares outstanding
  • Compared to 1 year ago, EMCG has a worse debt to assets ratio.
EMCG Yearly Shares OutstandingEMCG Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M
EMCG Yearly Total Debt VS Total AssetsEMCG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • EMCG has an Altman-Z score of 1.97. This is not the best score and indicates that EMCG is in the grey zone with still only limited risk for bankruptcy at the moment.
  • EMCG has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 1.97
ROIC/WACCN/A
WACCN/A
EMCG Yearly LT Debt VS Equity VS FCFEMCG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 0.02 indicates that EMCG may have some problems paying its short term obligations.
  • EMCG has a Quick Ratio of 0.02. This is a bad value and indicates that EMCG is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
EMCG Yearly Current Assets VS Current LiabilitesEMCG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. EMCG Growth Analysis

3.1 Past

  • EMCG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.03%.
EPS 1Y (TTM)-31.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-147.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. EMCG Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 68.75 indicates a quite expensive valuation of EMCG.
  • The average S&P500 Price/Earnings ratio is at 26.11. EMCG is valued rather expensively when compared to this.
Industry RankSector Rank
PE 68.75
Fwd PE N/A
EMCG Price Earnings VS Forward Price EarningsEMCG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EMCG Per share dataEMCG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EMCG Dividend Analysis

5.1 Amount

  • No dividends for EMCG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

EMCG Fundamentals: All Metrics, Ratios and Statistics

EMBRACE CHANGE ACQUISITION C

NASDAQ:EMCG (8/20/2025, 8:00:01 PM)

11

-1.2 (-9.84%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-26
Earnings (Next)11-03
Inst Owners48.39%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap26.62M
Revenue(TTM)N/A
Net Income(TTM)1.05M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 68.75
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)0.16
EY1.45%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS8.34
TBVpS8.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.96%
ROE 5.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)3.45%
ROA(5y)N/A
ROE(3y)4.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z 1.97
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-147.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-250.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-250.5%
OCF growth 3YN/A
OCF growth 5YN/A

EMBRACE CHANGE ACQUISITION C / EMCG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EMBRACE CHANGE ACQUISITION C?

ChartMill assigns a fundamental rating of 1 / 10 to EMCG.


Can you provide the valuation status for EMBRACE CHANGE ACQUISITION C?

ChartMill assigns a valuation rating of 0 / 10 to EMBRACE CHANGE ACQUISITION C (EMCG). This can be considered as Overvalued.


What is the profitability of EMCG stock?

EMBRACE CHANGE ACQUISITION C (EMCG) has a profitability rating of 1 / 10.